





## Inspire more movement

onsior® (robenacoxib)

## Onsior 6 mg tablets for cats

Now approved for the treatment of pain and inflammation associated with acute or chronic musculoskeletal disorders.<sup>1</sup>







### Onsior® (robenacoxib) offers convenience for vets and pet owners<sup>1,9</sup>

- Small flavoured tablets are easy to administer
- Can be given without food or with a small quantity of food
- Majority of cats can be treated with just 1 tablet per day
- Some cat owners prefer tablet medication to liquid<sup>2</sup>





### Simple dosing:

| Body weight (kg)  | 2.5 to < 6 | 6 to 12 |
|-------------------|------------|---------|
| Number of tablets | NA         | NA NA   |

### **Indication for use:**

Onsior (robenacoxib) 6 mg tablets for cats now approved for the treatment of pain and inflammation associated with acute or chronic musculoskeletal disorders (CMSD) in cats

Radiographic evidence of DJD in cats appears to be high<sup>5</sup>



Reported to be affected

## Long-term safety when cats with chronic musculoskeletal disorders received Onsior®8

Robenacoxib was well tolerated when administered orally for up to 12 weeks at the recommended therapeutic dose of 1 mg/kg day



### Large sample size

494 cats evaluated<sup>†</sup>


- 267 cats received robenacoxib
- 271 cats received placebo



### **Combined analysis**

Four field studies evaluating cats with CMSD

- Prospective
- Blinded
- Placebo controlled



**ALL CATS** 

Onsior's chronic use indication now increases the range of available treatment possibilities for CMSD and has a high safety margin?. What will you choose for your next case?

# Field study results seen when 109 cats with chronic musculoskeletal disorders received Onsior vs. placebo<sup>6</sup>

#### **PET OWNER ASSESSMENTS**

Pet owners saw the benefit of Onsior for their cats:†

### **Client Specific Outcome Measure**

- Impaired activities unique to the cat were assessed over time
- Significantly better performance of daily activities with robenacoxib over the 6 weeks of treatment

A clinically meaningful reduction in disability with 6 weeks of robenacoxib treatment

P= 0.01

Pet owner assessment tool with reported reliability, responsiveness and concurrent validity<sup>9</sup>

50% reduction in pain and disability

Temperament and happiness scores were also significantly (P<0.05) higher (better) with robenacoxib compared to placebo



#### **ACTIVITY MONITORING RESULTS**

Innovative at home activity monitoring was used to measure benefits of Onsior

Cats spent approximately 80% of the day resting<sup>7</sup>

Marked improvement in pattern of activity from 8pm – 8am‡



Total activity counts (24 hour) were also higher with robenacoxib



Improvement in activity was seen within 3 weeks, and continued over 6 weeks



‡8 pm to 8 am assessment period. Cats are most active during the evening and early morning. †Parallel-group comparison of groups over days 1-42. Owners blinded to treatment.



### Onsior 6 mg tablets for cats

## Inspiring more movement and helping get cats back to doing what they love!

- Effective treatment of pain and inflammation associated with chronic musculoskeletal disorders<sup>1,6</sup>
  - Improved activity patterns measured by state-of-the-art monitoring methods
  - Owners saw a significant improvement in their cat's ability to perform daily activities, temperament and happiness
- Well tolerated for long periods\* in cats WITH chronic musculoskeletal disorders<sup>8,9</sup>
  - Large sample size used to evaluate the safety of Onsior in clinically affected cats
  - Oral dose of 1 mg/kg day a dose with proven efficacy

Elanco, Onsior and the Diagonal Bar are trademarks of Elanco or its affiliates.

- No significant differences in adverse event frequency, gastro-intestinal parameters or renal/hepatic parameters between Onsior & placebo treated cats
- Flavoured tablet simple to dose, easy to give

\*Up to 12 weeks

© 2019 Flanco or its affiliates.









#### References

- 1. Summary of Product Characteristics: Onsior 6 mg tablets for cats.
- 2. Sivén, M. et al. (2017) Difficulties in administration of oral medication formulations to pet cats: an e-survey of cat owners. Veterinary Record. 180, 250
- 3. Lascelles BDX. Feline Degenerative Joint Disease. Veterinary Surgery. 2010; 39: 2-13.
- 4. Lascelles BDX et al (2010) Cross sectional Study of the prevalence of radiographic DJD in domesticated cats. Vet Surg 2010 39: 535.
- 5. Hardie EM, Roe SC and Martin FR. Radiographic evidence of degenerative joint disease in geriatric cats: 100 cases (1994-1997). JAVMA. 2002;5(1):628-632.
- 6. Lascelles BDX, King JN & Archer Thompson NJ (2018) Elanco Data on File.
- 7. Horn JA et al. Home range, habitat use and activity patterns of free-roaming domestic cats. The Journal of Wildlife Management 2011; 75(5): 1177-1185
- **8.** P16.4 Poster EAVPT2018 Onsior cat field study. King J et al (2018) Clinical safety of robenacoxib (Onsior) in cats with chronic-musculoskeletal disorder or osteoarthritis.
- 9. https://www.ema.europa.eu/documents/variation-report/onsior-v-c-127-ii-0018-q-epar-assessment-report-variation\_en.pdf







Onsior contains active ingredient robenacoxib. Onsior is indicated for the treatment of pain and inflammation associated with acute or chronic musculoskeletal disorders in cats. Legal category POM-V in UK, POM in IE. Further information regarding side effects, precautions, warnings and contraindications is available on the product SPC, product packing and leaflets. Further information can also be found website of the European medicines authority http://www.ema.europa.eu/. Storage instructions: Store below 25 °C.

For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco Animal Health, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL.

Elanco, Onsior and the Diagonal Bar are trademarks of Elanco or its affiliates. © 2019 Elanco or its affiliates.

BICAFONS00030

Use medicines responsibly: www.noah.co.uk/responsible www.apha.ie

